Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020111 · ClinicalTrials.gov registry record · Phase 1
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00020111: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00020111 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00020111, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in treating young patients with leukemia or lymphoma.
Interventions
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020111
The ClinicalTrials.gov registry entry for NCT00020111 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arsenic trioxide is the first listed.
NCT00020111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020111 about?
NCT00020111 is a clinical study titled "Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in treating young patients with leukemia or lymphoma.
What is the current status of trial NCT00020111?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-03.
What interventions are being tested in trial NCT00020111?
The interventions under investigation include: arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00020111?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.